Daniel Breeyear
Psychiatric/Mental Health · Niskayuna, NYNPI 1922620178
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 56.0% of the total. 2025 is the largest year on record at $96,369, more than ten times the $1,330 reported in 2021. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 728 payments — averaging $204.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$83K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$57K
- Alkermes, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$732
- plus $4K from 15 others
What the payments were for
- Consulting fees$33,06322%
- Speaking & faculty fees$68,75046%
- Travel & lodging$29,67820%
- Food & beverage$17,28412%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 176 | $83,334 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 174 | $57,075 |
| Alkermes, Inc. | 39 | $1,567 |
| AbbVie | 56 | $1,191 |
| Johnson & Johnson | 54 | $1,187 |
| Otsuka America Pharmaceutical, Inc. | 41 | $732 |
| Neurocrine Biosciences, Inc. | 34 | $604 |
| Vanda Pharmaceuticals Inc. | 27 | $597 |
| Lundbeck LLC | 25 | $508 |
| Teva Pharmaceuticals USA, Inc. | 11 | $454 |
| Corium, LLC | 26 | $434 |
| Novo Nordisk | 17 | $371 |
| Sunovion Pharmaceuticals Inc. | 14 | $190 |
| Supernus Pharmaceuticals, Inc. | 8 | $141 |
| Ironshore Pharmaceuticals Inc. | 6 | $137 |
| Indivior Inc. | 7 | $128 |
| Lilly USA, LLC | 4 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $71 |
| Bausch Health US, LLC | 2 | $45 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$148,893 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 21 | $69,167 |
| SpravatoEsketamine Hcl | 14 | $15,752 |
| TrintellixVortioxetine Hydrobromide | 18 | $8,738 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $4,056 |
| Escitalopram Oxalate | 16 | $1,160 |
| Hydroxyzine Hcl | 13 | $320 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $225 |
| Bupropion XlBupropion Hcl | 12 | $171 |
| Quetiapine Fumarate | 15 | $102 |
| Trazodone Hcl | 17 | $82 |
| Lamotrigine | 21 | $50 |
| Alprazolam | 17 | $32 |
| Citalopram HbrCitalopram Hydrobromide | 13 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $1,567 | $69,16721 claims |
| Johnson & JohnsonSpravato | $1,187 | $15,75214 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $71 | $12,79329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Niskayuna
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
- Matthew SharpePenfield$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.